A Phase 1/2 interventional study of TLT003 in Wiskott-Aldrich Syndrome (WAS), sponsored by Fondazione Telethon. Completed at 1 site in Italy. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Fondazione Telethon · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is phase I/II protocol to evaluate the safety and efficacy of WAS gene transfer into hematopoietic stem/progenitor cells for the treatment of Wiskott Aldrich Syndrome.
Wiskott-Aldrich Syndrome (WAS) is an X-linked primary immunodeficiency caused by mutations in the WAS gene which encodes the WAS protein (WASP), a cytoskeletal regulator which is expressed exclusively in hematopoietic cells.
41 studies on the registry are indexed under Wiskott-Aldrich Syndrome; 4 are open to participants now.
This study's enrollment of 8 is below the median of 20 across 29 interventional studies indexed under Wiskott-Aldrich Syndrome.
Browse Wiskott-Aldrich Syndrome studies →Fondazione Telethon is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of WAS defined by genetic mutation and at least one of the following criteria:
Negative search for a matched unrelated donor (10/10) or an adequate unrelated cord blood donor (5-6/6) within 4-6 months
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible subjects will receive intravenous (IV) infusion of TLT003 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included
Genetic: TLT003
TLT003 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
Also known as: Previously GSK2696275, Previously OTL-103
Safety of Reduced Conditioning Regimen
The absence of prolonged aplasia (defined as ANC \<0.5×10\^9/L \[\<500/μL\] at Day +60, with no evidence of BM recovery and requiring backup administration) was assumed as demonstrating the safety of the RIC regimen.
Time frame: Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)
Safety of Lentivirus Gene Transfer Into HSC
Safety and tolerability of lentiviral-transduced cell infusion. This will be evaluated on the basis of adverse events reporting and monitoring of the systemic reactions to cell infusion.
Time frame: after 48 hours after Telethon003 infusion
Sustained Engraftment of Genetically Corrected Haematopoietic Stem Cells in Peripheral Blood and/or in Bone Marrow
Engraftment is characterized by the presence of gene modified cells in the BM or PB compartments. The main indicator of gene correction is detection of the WAS LVV sequences in the HSPCs and their progeny. The VCN, which is the mean number of integrated copies of the vector sequences per cell genome, was measured using PCR-based methods in DNA samples extracted from BM and PB cell populations at various timepoints post-treatment. Adequate engraftment was defined as either ≥0.04 VCN/cell in BM CD34+ cells or ≥0.01 VCN/cell in PB CD3+ cells.
Time frame: at 1 year after Telethon003 infusion
Presence of Detectable Vector-derived WASP
The percentage of subjects who present the proportion of PB cells expressing WASP was assessed by flow cytometry analysis.
Time frame: Median duration: 11.1 years (range: 8.01 -13.3 years)
Improved T-cell Functions
Improvement in in vitro T-cell proliferation was assessed upon stimulation with 3 doses of anti-immobilized CD3 (CD3i) monoclonal antibodies ≥1 year after Telethon003 infusion (as compared with pre-GT values) in PBMC and/or T-cell lines. The degree of correction was evaluated with respect to healthy controls.
Time frame: Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)
Antigen-specific Responses to Vaccination
The ability to mount a protective humoral response to at least 4 out of 5 nominal antigens including antibodies to T-cell dependent antigens and conjugated or unconjugated polysaccharide antigens was measured after vaccination (planned \>1 year after Telethon003 infusion). If results were available on n \<5 antigens, the rule of at least n-1 applied to define success.
Time frame: Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)
Improved Platelet Count and MPV Normalization
Sustained increase in platelet count compared to baseline, analyzing the individual longitudinal profile
Time frame: up to 3 years after Telethon003 infusion
Overall Survival
Participant survival was monitored throughout the study.
Time frame: Follow up phase - Median duration: 11.1 years (range: 8.01 -13.3 years)
Lack of Immune Response to Transgene
Anti-WASP and anti-HIV-1 antibodies (anti-p24) were monitored to evaluate response to transgene and to vector, respectively.
Time frame: up to 3 years after Telethon003 infusion
Reduced Frequency of Severe Infections
Decrease in number of severe infections as evaluated in the second and third year after the treatment by clinical history, complete physical examinations, hematological and microbiological tests.
Time frame: up to 3 years after Telethon003 infusion
Reduced Bruising and Bleeding Episodes
Reduction in bruising and/or bleeding manifestations when present, as assessed by clinical monitoring, compared to clinical history
Time frame: 3 years
Reduced Autoimmunity Phenomena and Eczema
Reduction in laboratory markers (number and titer of antibody when available) and/or clinical manifestations of autoimmunity, as evaluated by organ-specific and systemic autoantibodies, imaging and clinical follow-up, compared to clinical history. Reduction in eczema as evaluated by clinical score
Time frame: 3 years
Improved Quality of Life
Improved quality of life, measured after the first year of treatment by reduced hospitalization, reduced requirement of drugs, school attendance, social activities.
Time frame: 3 year
Multilineage Engraftment of Genetically Corrected Cells
≥0.04 VCN/cell on all the available peripheral blood and/or bone marrow cell subpopulations (BM subpopulations: GlyA+, CD15+, CD61+, CD3+, CD19+, CD56+; PB subpopulations: CD15+, CD19+, CD56+)
Time frame: 3 years
Overall Safety of the Treatment
Recording of AE, AR, SAE/SAR, UAR, SUSAR
Time frame: 8 years
| Milestone | OTL-103 Gene Therapy |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
The absence of prolonged aplasia (defined as ANC \<0.5×10\^9/L \[\<500/μL\] at Day +60, with no evidence of BM recovery and requiring backup administration) was assumed as demonstrating the safety of the RIC regimen.
| Participants | TLT003 Gene Therapy |
|---|---|
| Safety of Reduced Conditioning Regimen | 8 |
Safety and tolerability of lentiviral-transduced cell infusion. This will be evaluated on the basis of adverse events reporting and monitoring of the systemic reactions to cell infusion.
| Participants | TLT003 Gene Therapy |
|---|---|
| Safety of Lentivirus Gene Transfer Into HSC | 8 |
Engraftment is characterized by the presence of gene modified cells in the BM or PB compartments. The main indicator of gene correction is detection of the WAS LVV sequences in the HSPCs and their progeny. The VCN, which is the mean number of integrated copies of the vector sequences per cell genome, was measured using PCR-based methods in DNA samples extracted from BM and PB cell populations at various timepoints post-treatment. Adequate engraftment was defined as either ≥0.04 VCN/cell in BM CD34+ cells or ≥0.01 VCN/cell in PB CD3+ cells.
| Participants | TLT003 Gene Therapy |
|---|---|
| Sustained Engraftment of Genetically Corrected Haematopoietic Stem Cells in Peripheral Blood and/or in Bone Marrow | 8 |
The percentage of subjects who present the proportion of PB cells expressing WASP was assessed by flow cytometry analysis.
| Participants | TLT003 Gene Therapy |
|---|---|
| Presence of Detectable Vector-derived WASP | 8 |
Improvement in in vitro T-cell proliferation was assessed upon stimulation with 3 doses of anti-immobilized CD3 (CD3i) monoclonal antibodies ≥1 year after Telethon003 infusion (as compared with pre-GT values) in PBMC and/or T-cell lines. The degree of correction was evaluated with respect to healthy controls.
| Participants | TLT003 Gene Therapy |
|---|---|
| Improved T-cell Functions | 8 |
The ability to mount a protective humoral response to at least 4 out of 5 nominal antigens including antibodies to T-cell dependent antigens and conjugated or unconjugated polysaccharide antigens was measured after vaccination (planned \>1 year after Telethon003 infusion). If results were available on n \<5 antigens, the rule of at least n-1 applied to define success.
| participants | TLT003 Gene Therapy |
|---|---|
| Antigen-specific Responses to Vaccination | 7 |
Sustained increase in platelet count compared to baseline, analyzing the individual longitudinal profile
| Participants | TLT003 Gene Therapy |
|---|---|
| Improved Platelet Count and MPV Normalization | 8 |
Participant survival was monitored throughout the study.
| Participants | TLT003 Gene Therapy |
|---|---|
| Overall Survival | 8 |
Anti-WASP and anti-HIV-1 antibodies (anti-p24) were monitored to evaluate response to transgene and to vector, respectively.
| Participants | TLT003 Gene Therapy |
|---|---|
| Lack of Immune Response to Transgene | 8 |
Decrease in number of severe infections as evaluated in the second and third year after the treatment by clinical history, complete physical examinations, hematological and microbiological tests.
Results for this outcome have not been posted.
Reduction in bruising and/or bleeding manifestations when present, as assessed by clinical monitoring, compared to clinical history
Results for this outcome have not been posted.
Reduction in laboratory markers (number and titer of antibody when available) and/or clinical manifestations of autoimmunity, as evaluated by organ-specific and systemic autoantibodies, imaging and clinical follow-up, compared to clinical history. Reduction in eczema as evaluated by clinical score
Results for this outcome have not been posted.
Improved quality of life, measured after the first year of treatment by reduced hospitalization, reduced requirement of drugs, school attendance, social activities.
Results for this outcome have not been posted.
≥0.04 VCN/cell on all the available peripheral blood and/or bone marrow cell subpopulations (BM subpopulations: GlyA+, CD15+, CD61+, CD3+, CD19+, CD56+; PB subpopulations: CD15+, CD19+, CD56+)
Results for this outcome have not been posted.
Recording of AE, AR, SAE/SAR, UAR, SUSAR
Results for this outcome have not been posted.
Collected over Adverse events were reported in the statistical outputs from Screening onward. Post-treatment AEs were recorded during follow up - Median duration of follow-up was 11.1 (range: 8.0-13.3) years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTL-103 Gene Therapy | 0/8 (0%) | 8/8 (100%) | 8/8 (100%) |
| Event | OTL-103 Gene Therapy |
|---|---|
| PyrexiaGeneral disorders | 3/8 |
| Device related infectionInfections and infestations | 2/8 |
| Mesenteric lymphadenitisBlood and lymphatic system disorders | 1/8 |
| NeutropeniaBlood and lymphatic system disorders | 1/8 |
| VomitingGastrointestinal disorders | 1/8 |
| Food AllergyImmune system disorders | 1/8 |
| GastroenteritisInfections and infestations | 1/8 |
| Pneumonia aspirationInfections and infestations | 1/8 |
| AppendicitisInfections and infestations | 1/8 |
| Aspergillus infectionInfections and infestations | 1/8 |
| Event | OTL-103 Gene Therapy |
|---|---|
| PyrexiaGeneral disorders | 8/8 |
| Upper respiratory tract infectionInfections and infestations | 8/8 |
| Anti-platelet antibody positiveInvestigations | 8/8 |
| DiarrhoeaGastrointestinal disorders | 7/8 |
| PetechiaeSkin and subcutaneous tissue disorders | 7/8 |
| RhinitisInfections and infestations | 6/8 |
| HypokalaemiaMetabolism and nutrition disorders | 6/8 |
| EczemaSkin and subcutaneous tissue disorders | 6/8 |
| Ear infectionInfections and infestations | 5/8 |
| InfluenzaInfections and infestations | 5/8 |
paediatric population
| Age, Categorical(Participants) | OTL-103 Gene Therapy |
|---|---|
| <=18 years | 8 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | OTL-103 Gene Therapy |
|---|---|
| Female | 0 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | OTL-103 Gene Therapy |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 8 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | OTL-103 Gene Therapy |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | OTL-103 Gene Therapy |
|---|---|
| Italy | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2010 to primary completion in Oct 2023, 161 months.
Results were first posted in Apr 2025, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Telethon